Lymphokine-activated killer lymphocytes: National Cancer Institute clinical trials.
Clark
J
J
National Cancer Institute, Frederick, Maryland.
Longo
D L
DL
D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000628:therapy*; D014481:United States
D007376:Interleukin-2